地拉罗司对输血依赖型骨髓增生异常综合征患者的心脏效应:TELESTO研究
TELESTO研究是一项前瞻性、安慰剂对照、随机研究,评估铁螯合剂地拉罗司在低危或中危-1型骨髓增生异常综合征(MDS)伴铁过载患者中的作用。地拉罗司组因充血性心力衰竭(CHF)住院或心功能恶化的复合风险较安慰剂组显著降低(HR=0.23;95%CI:0.05,0.99;名义p=0.0322)。左心室射血分数、心室直径和质量或肺动脉压方面两组无显著差异。
要点
- 地拉罗司组因CHF住院或心功能恶化的复合风险较安慰剂组显著降低(HR=0.23;95%CI:0.05,0.99;名义p=0.0322)。
- 左心室射血分数、心室直径和质量或肺动脉压方面两组无显著差异。
- 绝对事件数较低,但入组患者较MDS患者平均年龄年轻,无严重心脏合并症且心血管风险特征中等。
核心结论
- 这些结果支持地拉罗司在预防该患者人群中铁过载所致心脏损害方面的有效性。
- 识别发生CHF的患者具有挑战性,因缺乏特异性的超声心动图特征。
- 治疗铁过载可能对预防这些患者的心功能障碍很重要,即使对于中等CHF风险的患者也是如此。
研究设计与样本
- TELESTO(NCT00940602)是一项前瞻性、安慰剂对照、随机研究,评估铁螯合剂地拉罗司在低危或中危-1型MDS伴铁过载患者中的作用。
- 在筛选期和治疗期间收集超声心动图参数。
主要发现
- 地拉罗司组因CHF住院或心功能恶化的复合风险较安慰剂组显著降低(HR=0.23;95%CI:0.05,0.99;名义p=0.0322)。
- 左心室射血分数、心室直径和质量或肺动脉压方面两组无显著差异。
- 绝对事件数较低,但入组患者较MDS患者平均年龄年轻,无严重心脏合并症且心血管风险特征中等。
局限性
- 绝对事件数较低,但入组患者较MDS患者平均年龄年轻,无严重心脏合并症且心血管风险特征中等。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Iron overload from repeated transfusions has a negative impact on cardiac function, and iron chelation therapy may help prevent cardiac dysfunction in transfusion-dependent patients with myelodysplastic syndromes (MDS). TELESTO (NCT00940602) was a prospective, placebo-controlled, randomised study to evaluate the iron chelator deferasirox in patients with low- or intermediate-1-risk MDS and iron overload. Echocardiographic parameters were collected at screening and during treatment. Patients receiving deferasirox experienced a significant decrease in the composite risk of hospitalisation for congestive heart failure (CHF) or worsening of cardiac function (HR = 0.23; 95% CI: 0.05, 0.99; nominal p = 0.0322) versus placebo. No significant differences between the arms were found in left ventricular ejection fraction, ventricular diameter and mass or pulmonary artery pressure. The absolute number of events was low, but the enrolled patients were younger than average for patients with MDS, with no serious cardiac comorbidities and a modest cardiovascular risk profile. These results support the effectiveness of deferasirox in preventing cardiac damage caused by iron overload in this patient population. Identification of patients developing CHF is challenging due to the lack of distinctive echocardiographic features. The treatment of iron overload may be important to prevent cardiac dysfunction in these patients, even those with moderate CHF risk.
引用
- Sarocchi M, Li J, Li X, et al. Cardiac effects of deferasirox in transfusion-dependent patients with myelodysplastic syndromes: TELESTO study. Br J Haematol. 2024. PMID: 38343073. doi:10.1111/bjh.19316
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。